CIDEC and metabolic dysfunction-associated steatohepatitis: The in vivo data herein expand those initial results and further demonstrate that silencing of Fsp27 and fenofibrate synergistically reduce body weight gain, visceral adiposity, hypertriglyceridemia, liver oxidative stress, and steatohepatitis in a diet-induced mouse model of NASH (Fig. 8).